Lulizumab pegol - Bristol-Myers Squibb

Drug Profile

Lulizumab pegol - Bristol-Myers Squibb

Alternative Names: BMS-931699; Lulizumab

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action CD28 antigen modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 29 Nov 2017 Bristol-Myers Squibb terminates a phase II trial because of inability to meet protocol objectives for Systemic lupus erythematosus in USA, Canada, Brazil, Mexico, Puerto Rico, Argentina, Chile, Colombia, Peru, Japan, South Korea, Taiwan, South Africa, France, Germany, Hungary, Italy, Poland, Romania, Russia, Lebanon, Netherlands and Spain (SC) (NCT02265744)
  • 03 Mar 2017 Bristol Meyers Squibb plans a phase I trial in Healthy volunteers in USA (NCT03058822)
  • 01 Oct 2016 Phase-II clinical trials in Sjogren's syndrome in USA (SC) (NCT02843659)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top